Veracyte is trading 56.57% down at $22.20 after its November 4 earnings report raised concerns about slower growth. - Third-quarter revenue and adjusted earnings beat estimates, but Decipher Prostate volumes fell short of management’s expectations. - Veracyte narrowed its 2026 revenue outlook, lowered testing-revenue guidance and outlined a more cautious growth outlook; analyst target cuts added pressure. - The company-specific outlook appears to explain the decline more directly than broader market or biotech trends. The reported $100 million buyback did not offset growth concerns.